Clinical study on Ganbi decoction in treating antituberculotic agent-caused liver injury

Xian Yin-sheng; Wang Zuo-ren; Gong Xian-feng; Huang Bao-zhong

doi:10.1007/BF02857355

Your Location：

Home >

Browse articles >

Clinical study on Ganbi decoction in treating antituberculotic agent-caused liver injury

Updated：2021-08-27

- Clinical study on Ganbi decoction in treating antituberculotic agent-caused liver injury
- Chinese Journal of Integrative Medicine Vol. 12, Issue 2, Pages: 107-111(2006)
- Affiliations：
  
  1. Department of Surgery on Liver and Gallbladder, The First Hospital of Xi’an Jiaotong University,Xi’an
  2. Xi’an Tuberculosis Hospital,China
  3. Xi’an Hospital of Traditional Chinese Medicine,China
- Author bio：
- Funds：
- DOI：10.1007/BF02857355
  CLC：
- Published：2006，
Scan for full text
Yin-sheng, X., Zuo-ren, W., Xian-feng, G. et al. Clinical study on Ganbi decoction in treating antituberculotic agent-caused liver injury., Chin. J. Integr. Med. 12, 107–111 (2006). https://doi.org/10.1007/BF02857355

Xian Yin-sheng, Wang Zuo-ren, Gong Xian-feng, et al. Clinical study on Ganbi decoction in treating antituberculotic agent-caused liver injury. [J]. Chinese Journal of Integrative Medicine 12(2):107-111(2006)
Yin-sheng, X., Zuo-ren, W., Xian-feng, G. et al. Clinical study on Ganbi decoction in treating antituberculotic agent-caused liver injury., Chin. J. Integr. Med. 12, 107–111 (2006). https://doi.org/10.1007/BF02857355 DOI：

Xian Yin-sheng, Wang Zuo-ren, Gong Xian-feng, et al. Clinical study on Ganbi decoction in treating antituberculotic agent-caused liver injury. [J]. Chinese Journal of Integrative Medicine 12(2):107-111(2006) DOI： 10.1007/BF02857355.

摘要

Objective: To study the effect and mechanism of Ganbi decoction (GBD) in treating patients with antituberculotic agent caused liver injury (ATB-LI).Methods: One hundred and twenty-eight patients with ATB-LI were randomly assigned to the treated group (n = 66) and the control group (n = 62) with the envelop method. Meanwhile

60 healthy persons were selected as the healthy control group. The treated group was treated by GBD one dose every day with the constituents modified depending on patients’ symptoms

and the control group was treated with glucuronolactone tablets and inosine injection. One week was taken as one treatment course. The changes of clinical syndromes

physical signs

T-lymphycyte sub-groups and serum level of nitric oxide (NO) were observed before and after treatment and the recovery time of liver function was recorded. The outcome was compared with that in the healthy control group.Results: In the treated group

28 patients (42.4%) were cured

30 (45.5%) improved and 8 (12.1%) ineffectively cured

the total effective rate being 87.9% (58/66). In the control group

17 patients (27.4%) were cured

24 (38.7%) improved

and 21 (33.9%) ineffectively cured

the total effective rate being 66. 1 % (41/62). The total effective rate in the treated group was significantly higher than that in the control group (P< 0. 05). Liver function was improved in both groups

recovery time in the treated group was 12.0 ±7.0 days

which was significantly shorter than that in the control group (16.0 ±8.0 days)

showing significant difference between the two groups (P< 0.05). The levels of CD3

CD4 and CD8 were significantly higher and level of NO significantly lower in the two groups of patients than those in the healthy control group (P< 0.05)

but these parameters were improved more significantly in the treated group after treatment

when compared with those before treatment or with those in the control group

all showing significant difference (P< 0.05).Conclusion: GBD could prevent ATB-LI

and its mechanism could be by way of reducing NO production induced by endotoxin of macrophage and stimulating the proliferation of T-lymphycyte to elevate immunity.

Abstract

60 healthy persons were selected as the healthy control group. The treated group was treated by GBD one dose every day with the constituents modified depending on patients’ symptoms

and the control group was treated with glucuronolactone tablets and inosine injection. One week was taken as one treatment course. The changes of clinical syndromes

physical signs

28 patients (42.4%) were cured

30 (45.5%) improved and 8 (12.1%) ineffectively cured

the total effective rate being 87.9% (58/66). In the control group

17 patients (27.4%) were cured

24 (38.7%) improved

and 21 (33.9%) ineffectively cured

recovery time in the treated group was 12.0 ±7.0 days

which was significantly shorter than that in the control group (16.0 ±8.0 days)

showing significant difference between the two groups (P< 0.05). The levels of CD3

CD4 and CD8 were significantly higher and level of NO significantly lower in the two groups of patients than those in the healthy control group (P< 0.05)

but these parameters were improved more significantly in the treated group after treatment

when compared with those before treatment or with those in the control group

all showing significant difference (P< 0.05).Conclusion: GBD could prevent ATB-LI

and its mechanism could be by way of reducing NO production induced by endotoxin of macrophage and stimulating the proliferation of T-lymphycyte to elevate immunity.

关键词

Ganbi Decoctionanti-tuberculosis agentliver injury

Keywords

Ganbi Decoctionanti-tuberculosis agentliver injury

references

Wu YN, Xie CL, Liu P. The study progress of the relationship of nitric oxide and liver disease. Chin J Integr Tradit West Med Liver Dis 2002; 12(6): 379–380.

Wang H, Wang QM. The prevention and cure progress on post-antituberculotic liver injury. Chin J Clin Hepatol 1990; 6(3): 125–126.

Liang KH, editor. Liver disease. Beijing: People’s Medical Publishing House, 1995: 750.

State Administration of Traditional Chinese Medicine. Criteria of diagnosis and therapeutic efficacy of diseases and syndromes in traditional Chinese medicine 1995: 10.

Xiao HP. The progress of prevention and treatment on tuberculosis. Shanghai: Publishing House of Fudan University, 2004: 6–13.

Hong L. Antituberculotic medicine and liver injury. Intermediate Med J 1994; 29(11): 9–11.

Yuan HP, Li YQ. The mechanism and treatment of drug induced liver disease. Shandong Med 2004; 44 (10): 54–55.

Zhang XL, Quan QZ, Sun ZQ, et al. The action of NO in acute liver injury of mice caused by ConA. Chin J Gastroenterol Hepatol 2003; 11(3): 217–218.

Tan YJ, Zhang YB, Feng DY, et al. The change and the clinical significance of peripheral blood Th1/Th2 cells in patients with pulmonary tuberculosis. Chin J Tuberc Respir Dis 2004; 27(6): 385–389.

Ma Y, Wang YM, Wang JW. The action of tuberculosis’s Ag5 in the diagnosis of pulmonary tuberculosis. Chin J Tuberc Respir Dis 1985; 8(2): 71.

Liang Y, Cui RL. Progression on studies of anti-inflammatory and immune function of saikosaponin and its homologues. Chin J Integr Tradit West Med 1998; 18(7): 446–447.

Weng WL, Fang ST, editors. Clin Chin Materia Medica 1998; 5 (1): 1218.

Moon A. The effect of Radix Glycyrrhizae to rats on glucose aldehyde acidification. For Med Sci: TCM section. 1998; 20(3): 47–48.

Wang YM, editor. The pharmacology of traditional Chinese medicine. Shanghai: The Scientific and Technological Publishing House of Shanghai, 1998: 50.

Zu N, Li P. The physiological action and clinical significance of Saikosaponins. Chin J Inform TCM 2005; 12(4): 94–96.

FULL TEXT LINK

More>

Views

347

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Comparative study on the protective effects of Yinchenhao Decoction (茵陈蒿汤) against liver injury induced by α-naphthylisothiocyanate and carbon tetrachloride

Intervention effects of Jianpi Liqi Huoxue Decoction (健脾理气活血汤) on lipid peroxidative liver injury induced by alcohol

Effect of magnesium lithosperamate B on D-galactosamine induced liver injury in rats

Self-protection against triptolide-induced toxicity in human hepatic cells via Nrf2-ARE-NQO1 pathway

Related Author

No data

Related Institution

Department of Pharmacognosy, Heilongjiang University of Chinese Medicine

China Academy of Chinese Medical Sciences

First Hospital, Harbin Medical University

Institute of Liver Diseases, Shuguang Hospital, Shanghai University of TCM

College of Pharmacy, Wuhan University

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰